Bybit added six new TradFi perpetual contracts to its platform within a single day, expanding its lineup of stock-tracking derivatives across the pharmaceutical, healthcare, industrial, and finance sectors.
The exchange first listed perpetual contracts tracking Gilead Sciences ($GILD), Amgen ($AMGN), and Regeneron ($REGN), three major pharmaceutical and biotech names. Hours later, it followed with contracts tracking UnitedHealth Group ($UNH), General Electric ($GE), and JPMorgan Chase ($JPM), rounding out the day's additions with names spanning healthcare insurance, industrials, and banking.
Broadening Access to U.S. Equities
The rapid succession of listings reflects Bybit's ongoing push to expand its TradFi perpetuals offering, giving crypto-native traders leveraged, synthetic exposure to a wider swath of the U.S. stock market without requiring a traditional brokerage account. Each of the six companies represents a different corner of the market — from biotech innovation at Gilead and Regeneron, to healthcare insurance at UnitedHealth, industrial manufacturing at GE, and traditional banking at JPMorgan.
Perpetual contracts on individual equities let traders take leveraged long or short positions that track a stock's price without an expiration date, using periodic funding payments to keep the contract anchored to the underlying share price. The approach mirrors how crypto perpetuals have long functioned, now extended to a broader set of traditional securities.
Timing Around Earnings Season
The listings arrive amid a dense stretch of U.S. corporate earnings reports, a period when trading interest in individual stocks typically spikes as investors react to quarterly results. Bybit has used its TradFi division to launch a steady cadence of new stock-linked products in recent weeks, positioning the exchange to capture volume tied to earnings-driven volatility across sectors.
